These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 30513344)
1. A brief introduction of IgG-like bispecific antibody purification: Methods for removing product-related impurities. Li Y Protein Expr Purif; 2019 Mar; 155():112-119. PubMed ID: 30513344 [TBL] [Abstract][Full Text] [Related]
2. Removal of half antibody, hole-hole homodimer and aggregates during bispecific antibody purification using MMC ImpRes mixed-mode chromatography. Tang J; Zhang X; Chen T; Wang Y; Li Y Protein Expr Purif; 2020 Mar; 167():105529. PubMed ID: 31698035 [TBL] [Abstract][Full Text] [Related]
3. Removing a difficult-to-separate byproduct by Capto L affinity chromatography during the purification of a WuXiBody-based bispecific antibody. Wang Y; Chen X; Wang Y; Li Y Protein Expr Purif; 2020 Nov; 175():105713. PubMed ID: 32738439 [TBL] [Abstract][Full Text] [Related]
4. Protein L chromatography: A useful tool for monitoring/separating homodimers during the purification of IgG-like asymmetric bispecific antibodies. Chen X; Wang Y; Wang Y; Li Y Protein Expr Purif; 2020 Nov; 175():105711. PubMed ID: 32738435 [TBL] [Abstract][Full Text] [Related]
5. IgG-like bispecific antibody platforms with built-in purification-facilitating elements. Li Y Protein Expr Purif; 2021 Dec; 188():105955. PubMed ID: 34416361 [TBL] [Abstract][Full Text] [Related]
6. Removing light chain-missing byproducts and aggregates by Capto MMC ImpRes mixed-mode chromatography during the purification of two WuXiBody-based bispecific antibodies. Wan Y; Zhang T; Wang Y; Wang Y; Li Y Protein Expr Purif; 2020 Nov; 175():105712. PubMed ID: 32738441 [TBL] [Abstract][Full Text] [Related]
7. Immunoglobulin-binding protein-based affinity chromatography in bispecific antibody purification: Functions beyond product capture. Li Y Protein Expr Purif; 2021 Dec; 188():105976. PubMed ID: 34537355 [TBL] [Abstract][Full Text] [Related]
8. "BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells. Litvak-Greenfeld D; Vaks L; Dror S; Nahary L; Benhar I Methods Mol Biol; 2019; 1904():431-454. PubMed ID: 30539485 [TBL] [Abstract][Full Text] [Related]
10. Development of a novel affinity chromatography resin for platform purification of bispecific antibodies with modified protein a binding avidity. Tustian AD; Laurin L; Ihre H; Tran T; Stairs R; Bak H Biotechnol Prog; 2018 May; 34(3):650-658. PubMed ID: 29464924 [TBL] [Abstract][Full Text] [Related]
11. Rearranging the domain order of a diabody-based IgG-like bispecific antibody enhances its antitumor activity and improves its degradation resistance and pharmacokinetics. Asano R; Shimomura I; Konno S; Ito A; Masakari Y; Orimo R; Taki S; Arai K; Ogata H; Okada M; Furumoto S; Onitsuka M; Omasa T; Hayashi H; Katayose Y; Unno M; Kudo T; Umetsu M; Kumagai I MAbs; 2014; 6(5):1243-54. PubMed ID: 25517309 [TBL] [Abstract][Full Text] [Related]
12. Construction and production of an IgG-Like tetravalent bispecific antibody, IgG-single-chain Fv fusion. Lu D; Zhu Z Methods Mol Biol; 2014; 1060():185-213. PubMed ID: 24037843 [TBL] [Abstract][Full Text] [Related]
13. A potential downstream platform approach for WuXiBody-based IgG-like bispecific antibodies. Guo G; Han J; Wang Y; Li Y Protein Expr Purif; 2020 Sep; 173():105647. PubMed ID: 32334139 [TBL] [Abstract][Full Text] [Related]
14. Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies. Froning KJ; Leaver-Fay A; Wu X; Phan S; Gao L; Huang F; Pustilnik A; Bacica M; Houlihan K; Chai Q; Fitchett JR; Hendle J; Kuhlman B; Demarest SJ Protein Sci; 2017 Oct; 26(10):2021-2038. PubMed ID: 28726352 [TBL] [Abstract][Full Text] [Related]
15. Fab-based bispecific antibody formats with robust biophysical properties and biological activity. Wu X; Sereno AJ; Huang F; Lewis SM; Lieu RL; Weldon C; Torres C; Fine C; Batt MA; Fitchett JR; Glasebrook AL; Kuhlman B; Demarest SJ MAbs; 2015; 7(3):470-82. PubMed ID: 25774965 [TBL] [Abstract][Full Text] [Related]
16. Development of purification processes for fully human bispecific antibodies based upon modification of protein A binding avidity. Tustian AD; Endicott C; Adams B; Mattila J; Bak H MAbs; 2016; 8(4):828-38. PubMed ID: 26963837 [TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin Gamma-Like Therapeutic Bispecific Antibody Formats for Tumor Therapy. Chen S; Li L; Zhang F; Wang Y; Hu Y; Zhao L J Immunol Res; 2019; 2019():4516041. PubMed ID: 30886871 [TBL] [Abstract][Full Text] [Related]
18. Coupling Mixed-Mode Size Exclusion Chromatography with Native Mass Spectrometry for Sensitive Detection and Quantitation of Homodimer Impurities in Bispecific IgG. Yan Y; Xing T; Wang S; Daly TJ; Li N Anal Chem; 2019 Sep; 91(17):11417-11424. PubMed ID: 31373790 [TBL] [Abstract][Full Text] [Related]
19. Application of pH-salt dual gradient elution in purifying a WuXiBody-based bispecific antibody by MMC ImpRes mixed-mode chromatography. Wan Y; Wang Y; Zhang T; Zhang S; Wang Y; Li Y Protein Expr Purif; 2021 May; 181():105822. PubMed ID: 33429037 [TBL] [Abstract][Full Text] [Related]
20. Production of IgG1-based bispecific antibody without extra cysteine residue via intein-mediated protein trans-splicing. Akiba H; Ise T; Nagata S; Kamada H; Ohno H; Tsumoto K Sci Rep; 2021 Sep; 11(1):19411. PubMed ID: 34593913 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]